Supernus Pharmaceuticals, Inc. Share Price
NASDAQ: SUPN | Mid CapSupernus Pharmaceuticals, Inc. Stock Performance
Supernus Pharmaceuticals, Inc. Share Price Today
As of 19 September 2026, Supernus Pharmaceuticals, Inc.'s share price is $41.98. The stock opened at $42.46, compared to its previous close of $42.91. During today's trading session, Supernus Pharmaceuticals, Inc.'s share price traded between $41.65 and $42.48, with an average price of $42.06. Over the past 52 weeks, the stock has recorded a high of $59.45 and a low of $40.52. In terms of performance, Supernus Pharmaceuticals, Inc.'s share price has declined by 18.77% over the last six months and is down 12.16% on a year-on-year basis.
Supernus Pharmaceuticals, Inc. Share Price Chart
Supernus Pharmaceuticals, Inc. Quarterly Profit & Loss
All figures in USD
Supernus Pharmaceuticals, Inc. Annual Profit & Loss
All figures in USD
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
Supernus Pharmaceuticals, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Sep 2026 | $44.52 | $41.99 | -4.98% |
Aug 2026 | $50.45 | $44.19 | -0.99% |
Jul 2026 | $46.95 | $44.63 | -4.08% |
Jun 2026 | $46.02 | $46.53 | +0.85% |
May 2026 | $47.81 | $46.14 | -3.87% |
Apr 2026 | $51.37 | $48.00 | -7.12% |
Mar 2026 | $54.52 | $51.68 | -5.64% |
Feb 2026 | $48.63 | $54.77 | +13.70% |
Jan 2026 | $49.27 | $48.17 | -3.03% |
Dec 2025 | $45.45 | $49.67 | +8.72% |
Nov 2025 | $55.15 | $45.69 | -17.11% |
Oct 2025 | $47.29 | $55.12 | +15.34% |
SUPN Share Price FAQs
What is Supernus Pharmaceuticals, Inc. share price today?
What is the 52 week high and 52 week low of Supernus Pharmaceuticals, Inc. stock?
What is SUPN's market capitalisation today?
What is SUPN's net income for the last quarter?
What is the 5 year returns of SUPN?
What is the high & low stock price of SUPN today?
Can I buy SUPN shares in India?